论文部分内容阅读
已有研究证实,首个口服可逆性ADP受体拮抗剂AZD6140在稳定型冠心病患者中所获得的平均血小板抑制水平高于氯吡格雷。美国学者Cannon等的DISPERSE-2研究主要比较非ST段抬高急性冠脉综合征(NSTEACS)患者使用氯吡格雷与AZD6140的安全性、耐受性和初期有效性。
It has been confirmed that the first oral reversible ADP receptor antagonist AZD6140 in patients with stable coronary heart disease obtained an average platelet inhibitory level higher than that of clopidogrel. The DISPERSE-2 study by American scholar Cannon et al. Compared the safety, tolerability and initial efficacy of clopidogrel with AZD6140 in patients with non-ST-elevation acute coronary syndrome (NSTEACS).